National Graphite Corp.

NGRC

US6362682030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:00:12 2024-07-03 EDT			5-day change	1st Jan Change
0.051 ^USD	+2.00%		+2.00%	-1.92%

2015	Wolfgang Kochs to Resign from National Graphite Corp. as Director and Chief Financial Officer	CI
2015	National Graphite Corp. cancelled the transaction announced on October 17, 2012	CI

National Graphite Corp. Appoints Howard Bouch as Director, CFO and Treasurer

November 09, 2012 at 09:12 am

National Graphite Corp. announced that at a meeting of the board of directors held on November 5, 2012, Howard Bouch was appointed as a director. Howard Bouch serve as CFO/Treasurer of the company.

Mr. Bouch is also a director of Viavid Broadcasting Inc., Tiger Oil and Energy Inc., Dewmar International BMC Inc., and Black Hawk Exploration.

Latest news about National Graphite Corp.

Wolfgang Kochs to Resign from National Graphite Corp. as Director and Chief Financial Officer	15-12-11	CI
National Graphite Corp. cancelled the transaction announced on October 17, 2012	15-10-16	CI
National Graphite Corp. Announces Executive Changes	15-10-05	CI
National Graphite Corp. Announces Management Changes	14-10-28	CI
National Graphite Corp. entered in a share exchange agreement to acquire Biotech Development Corp. from Ulrike Dickmann, Axel Kutscher and Frank Petermeyer for $10 million.	14-10-28	CI
National Graphite Corp. completed the acquisition of Biotech Development Corp. from Ulrike Dickmann, Axel Kutscher and Frank Petermeyer.	14-10-28	CI
National Graphite Corp. announced that it has received $0.1 million in funding.	14-10-17	CI
National Graphite Corp. Cancels Chedic Graphite Drill Program	13-12-11	CI
National Graphite Corp. Signs Strategic Alliance with American Graphene LLC	13-06-03	CI
National Graphite Initiates Environmental Study on Chedic Graphite Property	13-05-23	CI
National Graphite Corp. Intends to Drill Chedic Graphite Property	13-03-05	CI
National Graphite Corp. Announces Samples from Chedic Graphite Prospect Yields 25% to 40% Grade with 1,000,000 Ton Potential	12-11-30	CI
National Graphite Corp. Appoints Howard Bouch as Director, CFO and Treasurer	12-11-09	CI
National Graphite Corp. Discovers Second High Grade Zone at its Nevada Graphite Mine	12-10-10	CI
National Graphite Corp. Announces Completion of Geophysics Survey on Nevada Graphite Property	12-09-12	CI
National Graphite Corp. completed the acquisition of 300 acres of property adjacent to the Chedic/Voltaire property in NW Nevada from GeoXplor Corp.	12-09-11	CI
National Graphite Corp. Expands Graphite Land Holdings in NW Nevada	12-09-05	CI
National Graphite Corp. agreed to acquire 300 acres of property adjacent to the Chedic/Voltaire property in NW Nevada from GeoXplor Corp.	12-09-04	CI
National Graphite Corp. will Change its Ticker to NGRC from LUCB	12-06-06	CI
Lucky Boy Silver Corp has Changed its Name to National Graphite Corp	12-06-06	CI
Lucky Boy Silver Corp acquired Chedic graphite property from GeoXplor Corp. for $1.7 million.	12-05-01	CI
National Graphite Corp. Acquires 65 Graphite Claim Block in Quebec, Canada	12-04-24	CI
Lucky Boy Silver Corp acquired 65 claims in Lochaber Township in Quebec from Habitants Minerals Ltd. for $0.1 million.	12-04-23	CI

National Graphite Corp., formerly Lucky Boy Silver Corporation, is a biopharmaceutical risk/cost-sharing company. The Company is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The Company operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NATIONAL GRAPHITE CORP.	-1.92%	7.87M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.55%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.14%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-46.81%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs